128 related articles for article (PubMed ID: 10235489)
1. CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo.
Nishimatsu H; Takeuchi T; Ueki T; Kajiwara T; Moriyama N; Ishida T; Li B; Kakizoe T; Kitamura T
Cancer Immunol Immunother; 1999 Apr; 48(1):56-61. PubMed ID: 10235489
[TBL] [Abstract][Full Text] [Related]
2. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
4. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
5. T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas.
Sayers TJ; Brooks AD; Seki N; Smyth MJ; Yagita H; Blazar BR; Malyguine AM
J Leukoc Biol; 2000 Jul; 68(1):81-6. PubMed ID: 10914493
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
7. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts.
Seino K; Kayagaki N; Tsukada N; Fukao K; Yagita H; Okumura K
Transplantation; 1997 Oct; 64(7):1050-4. PubMed ID: 9381528
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the alloantibody response by CD95 ligand.
Arai H; Chan SY; Bishop DK; Nabel GJ
Nat Med; 1997 Aug; 3(8):843-8. PubMed ID: 9256273
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
Seki N; Hayakawa Y; Brooks AD; Wine J; Wiltrout RH; Yagita H; Tanner JE; Smyth MJ; Sayers TJ
Cancer Res; 2003 Jan; 63(1):207-13. PubMed ID: 12517799
[TBL] [Abstract][Full Text] [Related]
10. Expression of angiostatin cDNA in a murine renal cell carcinoma suppresses tumor growth in vivo.
Fukumori T; Nishitani Ma; Naroda T; Onishi T; Oka N; Kanayama Ho; Kagawa S
Urology; 2002 Jun; 59(6):973-7. PubMed ID: 12031397
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma.
Kudo S; Konda R; Obara W; Kudo D; Tani K; Nakamura Y; Fujioka T
Oncol Rep; 2007 Oct; 18(4):785-91. PubMed ID: 17786337
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma.
Ogushi T; Takahashi S; Takeuchi T; Urano T; Horie-Inoue K; Kumagai J; Kitamura T; Ouchi Y; Muramatsu M; Inoue S
Cancer Res; 2005 May; 65(9):3700-6. PubMed ID: 15867365
[TBL] [Abstract][Full Text] [Related]
13. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential.
Miyake H; Hara I; Yoshimura K; Eto H; Arakawa S; Wada S; Chihara K; Kamidono S
Cancer Res; 1996 May; 56(10):2440-5. PubMed ID: 8625325
[TBL] [Abstract][Full Text] [Related]
14. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential.
Miyake H; Hara I; Gohji K; Yamanaka K; Hara S; Arakawa S; Nakajima M; Kamidono S
Clin Cancer Res; 1999 Oct; 5(10):2824-9. PubMed ID: 10537348
[TBL] [Abstract][Full Text] [Related]
15. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
[TBL] [Abstract][Full Text] [Related]
16. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
Ali SA; Rees RC; Anderson DQ; Reed MW; Goepel JR; Brown NJ
Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
[TBL] [Abstract][Full Text] [Related]
17. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
18. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
[TBL] [Abstract][Full Text] [Related]
19. The influence of CD95L expression on tumor rejection in mice.
Igney FH; Behrens CK; Krammer PH
Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
